Full video transcriptClick to expand
Auto-generated transcript of @dietcoach4u's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So you want to lose over 100 pounds on GLP1 medicines like ouzimpic, well govi, semagluetide,
- 0:05terzepitide, manjaro, zepbounce, exinda, trolicity, or others.
- 0:09We're going to teach you how to do it today.
- 0:11We're going to get an amazing result.
- 0:13So my name is Dustin.
- 0:14I own Advanced Nutrition Solutions Two-Time Weight Loss Practice of the Year.
- 0:16We work with over 4,000 clients on 50 states, four countries, and we have helped hundreds
- 0:20lose over 100 pounds in 12 months, and this is how we're going to do it.
- 0:24Now, the medicines are good.
- 0:26If you're around 250 pounds, you'll lose around 40 to 50 pounds over the course of 16
- 0:31months.
- 0:32So in a year and a quarter, the average person who starts off at 250 pounds will lose between
- 0:3640 and 50 pounds.
- 0:38I know you're ant loss 100.
- 0:39I know your friend lost 7,000 pounds in six weeks.
- 0:42However, that is the minority.
- 0:45The average, according to the FDA studies, is somewhere between 40 and 50 pounds if you
- 0:49have a starting weight of 250.
- 0:50So how are we going to double those results to get you that much weight loss in a shorter
- 0:55time frame than the FDA studies?
- 0:58So this is how we're going to do it.
- 1:00Number one, we do need tracker calories.
- 1:02We need to know how many calories we're eating daily, so that way if we do plateau, we know
- 1:05how to fix that.
- 1:07It is hard to calculate how many calories your body needs by itself, especially with these
- 1:11medicines reducing your appetite so much.
- 1:14So we can help you here come up with a game plan, so that way you're eating the right
- 1:19amount of calories to facilitate weight loss.
- 1:21If you're eating the same amount of calories daily, then it's easy to make adjustments to
- 1:25continue making sure you're losing weight, especially body fat as we go.
- 1:29Number two, we're going to increase protein.
- 1:31Protein, 1999 study, 76% more fat burning, 80% more weight loss with a higher protein,
- 1:37lower carb diet, and that's not no carb, this isn't keto, we're still eating some carbs.
- 1:41We know the 2012 study with women with PCOS twice as much weight loss, twice as much fat
- 1:45burning with a higher protein, lower carb diet.
- 1:48We know that protein helps you burn more fat and helps you get that lean tone physique.
- 1:52You cannot get toned with showing off muscle under fat without protein.
- 1:57This is also going to protect you from a zimpic butt and a zimpic face.
- 1:59This is also going to keep your metabolism raging throughout the process.
- 2:04How much protein?
- 2:05We can help you calculate that also, however, at a very minimum, it's 100 grams, and to be
- 2:10quite honest with you, you need more than that.
- 2:12Number three, we're going to 30 minutes cardio a day.
- 2:15Walking counts as cardio, don't ever think this.
- 2:17This is going to help you burn an extra 200-300 calories each and every day, which is going
- 2:21to help you burn more fat in the long run.
- 2:23Number four, incredibly underrated, incredibly underrated.
- 2:27More important to cardio, in my opinion, with GOP-1 medicines and that's resistance training.
- 2:31Resistance training is anything that applies resistance to the muscle.
- 2:34So body weight exercises like push-ups, crunches, squats, wall sets, whether it's kettlebells,
- 2:38resistance bands, hand weights, free weights, gym or no gym, machines, whatever, all of that
- 2:43counts as resistance training.
- 2:45I like my clients to do four days a week.
- 2:46We do customized programming for our clients, including quick 10-minute at home workout.
- 2:51It's going to help you get toned, get shredded, get jacked, whatever the goal might be, and
- 2:55to help you keep your metabolism supercharged on GOP-1 medicines.
- 2:59Lastly, because of deficiencies in vitamins and minerals, which are very common with GOP-1
- 3:04use, we want to make sure you're getting enough vitamins and minerals in your diet.
- 3:07Vibing to minerals play a role with thyroid function, testosterone levels in men and women,
- 3:11insulin use cortisol and so many other hormones inside the body.
- 3:15So making sure you get enough fruits and veggies, whole grains, fermented foods, tropical
- 3:19fruits and more is going to be critical to help your body remain optimized in both energy
- 3:24levels, immune function, but also weight loss, toning and all that good stuff.
- 3:28So make sure you get your vitamins and minerals in, whether it's through whole foods or supplementation.
- 3:33You do this over the course of 12 months, you're going to be like our clients that lose 100 pounds
- 3:37in six months or 120 pounds in nine months or even more.
- 3:41So let's get you amazing results in 2024.
GLP-1 weight loss claims: separating real results from TikTok math
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide produce clinically significant weight loss in trials, averaging 15-22% of body weight over 68-72 weeks depending on the agent and dose, but discontinuation is associated with substantial weight regain as shown in the STEP 4 trial (Rubino et al., 2021, JAMA). Resistance training during GLP-1 therapy is a legitimate clinical strategy to preserve lean mass, since approximately 40% of weight lost on semaglutide in trials is lean tissue. Expecting 100 pounds of loss in six months falls well outside average trial outcomes and should not be presented as a typical or target result.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 weight loss claims: separating real results from TikTok math, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 weight loss claims: separating real results from TikTok math" from Dustin Holston the Biohacker. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide produce clinically significant weight loss in trials, averaging 15-22% of body weight over 68-72 weeks depending on the agent and dose, but discontinuation is associated with substantial weight regain as shown in the STEP 4 trial (Rubino et al.
The reason this review is not generic is the source wording and the canonical claim label "glp1 let s lose over 100 pounds with ozempic wegovy mounjaro zepb." In this clip, the useful excerpt is: "So you want to lose over 100 pounds on GLP1 medicines like ouzimpic, well govi, semagluetide, terzepitide, manjaro, zepbounce, exinda, trolicity, or others." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide produce clinically significant weight loss in trials, averaging 15-22% of body weight over 68-72 weeks depending on the agent and dose, but discontinuation is associated with substantial weight regain as shown in the STEP 4 trial (Rubino et al.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide produce clinically significant weight loss in trials, averaging 15-22% of body weight over 68-72 weeks depending on the agent and dose, but discontinuation is associated with substantial weight regain as shown in the STEP 4 trial (Rubino et al., 2021, JAMA). Resistance training during GLP-1 therapy is a legitimate clinical strategy to preserve lean mass, since approximately 40% of weight lost on semaglutide in trials is lean tissue. Expecting 100 pounds of loss in six months falls well outside average trial outcomes and should not be presented as a typical or target result.
- STEP 1 trial data (Wilding et al., 2021, NEJM): mean weight loss on semaglutide 2.4mg was 14.9% of body weight over 68 weeks, roughly 37 lbs from a 250 lb starting weight.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide produced up to 22.5% mean weight loss at the highest dose, significantly outperforming semaglutide in head-to-head comparisons.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial data (Wilding et al., 2021, NEJM): mean weight loss on semaglutide 2.4mg was 14.9% of body weight over 68 weeks, roughly 37 lbs from a 250 lb starting weight.
- SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide produced up to 22.5% mean weight loss at the highest dose, significantly outperforming semaglutide in head-to-head comparisons.
- STEP 4 trial (Rubino et al., 2021, JAMA): stopping semaglutide results in regain of approximately two-thirds of lost weight within one year, making the caption claim of losing 30 more lbs after stopping medication implausible for most people.
- Approximately 40% of weight lost on semaglutide in clinical trials is lean mass, which supports the creator's recommendation for resistance training as a preservation strategy.
- The specific study citations in this video (a 1999 protein study, a 2012 PCOS study) are presented without journal names or authors and cannot be independently verified as quoted.
- 100 lbs of weight loss in 6 months falls well outside average clinical trial outcomes and represents an extreme outlier, not a reasonable expectation for most GLP-1 users.
- Calorie tracking, protein optimization above 100g daily, and structured resistance training are all evidence-supported additions to GLP-1 therapy, even if the creator's specific statistics are imprecise.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dietcoach4u actually say?
The creator, Dustin, claims his nutrition practice has helped "hundreds lose over 100 pounds in 12 months" using GLP-1 medications combined with calorie tracking, high protein intake, cardio, and resistance training. He also states that the average person starting at 250 pounds will lose "between 40 and 50 pounds" over 16 months on GLP-1s alone, per FDA studies.
He then frames his program as a way to "double those results" through lifestyle additions. He cites a 1999 study claiming "76% more fat burning" with higher protein diets, a 2012 study showing doubled weight loss in women with PCOS on high-protein diets, and recommends 100+ grams of protein daily, 30 minutes of daily cardio, and four days of resistance training per week. He also flags vitamin and mineral deficiencies as a common concern with GLP-1 use.
Does the science back this up?
Partially, yes. The GLP-1 weight loss estimates he cites are in the right ballpark, and the lifestyle additions he recommends are genuinely evidence-supported. But the specific study citations are where things get slippery.
The semaglutide STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean weight loss of about 14.9% of body weight over 68 weeks. For someone starting at 250 pounds, that works out to roughly 37 pounds, which aligns reasonably well with his 40-50 pound estimate. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed even higher losses, up to 22.5% at the highest dose, so his estimate undersells tirzepatide specifically.
On protein, a high-protein diet's effect on fat oxidation and satiety is well-documented. Layman et al. (2003, Journal of Nutrition) showed meaningful body composition benefits from higher protein intake during weight loss. The exact "76% more fat burning" figure he quotes is vague and uncited by journal name, making it unverifiable as stated.
What did they get wrong (or right)?
He got the foundational lifestyle advice right. Calorie awareness, protein prioritization, resistance training to preserve lean mass, and micronutrient attention are all defensible recommendations supported by peer-reviewed literature. The concern about muscle loss on GLP-1s is real: Wilding et al. (2021) noted that roughly 40% of weight lost in the STEP 1 trial was lean mass, which is a legitimate clinical concern that resistance training can help address.
What he got wrong, or at least unverifiable, includes the specific study citations. A "1999 study" showing 76% more fat burning is not traceable without a journal name, author, or DOI. The "2012 PCOS study" showing doubled weight loss is similarly vague.
His claim of "hundreds" losing 100 pounds in 12 months is unverifiable and likely cherry-picked. The clinical trial data does not support this as a typical outcome. Presenting outlier results as achievable benchmarks for viewers is misleading, even if those individual cases are real.
He also mispronounces nearly every drug name in the video. That is not a safety issue, but it does raise questions about medical credibility.
What should you actually know?
GLP-1 medications are effective tools, not magic. The clinical trial data shows meaningful average weight loss, but "average" means half of people lose less. Adding structured lifestyle changes, especially resistance training and adequate protein, is genuinely supported by science and can improve outcomes beyond medication alone.
However, losing 100 pounds in six months is an extreme outlier result, not a reasonable expectation to set for 10,000 TikTok viewers. The STEP 1 and SURMOUNT-1 trials ran for over a year and showed averages well below that. If your starting weight is significantly higher than 250 pounds, larger absolute losses are possible, but the timeline this creator implies is not the norm.
The claim that someone stopped GLP-1 medication and "lost an additional 30 pounds in 3 months" from the caption is biologically implausible for most people. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that stopping semaglutide leads to weight regain averaging two-thirds of lost weight within a year. That caption claim should be treated with significant skepticism.
If you are considering GLP-1 therapy, talk to a licensed prescriber, not a TikTok nutrition coach, regardless of how many awards their practice has won.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dustin Holston the Biohacker · TikTok creator
10.5K views on this video
Let’s lose over 100 pounds with ozempic, wegovy, mounjaro, zepbound, Tirzepetide and Semaglutide. Our record is 100 in 6 months, stopped medicine and lost an additional 30 in 3 months. #diet #weightloss
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about step 1 trial data (wilding et al., 2021, nejm): mean?
STEP 1 trial data (Wilding et al., 2021, NEJM): mean weight loss on semaglutide 2.4mg was 14.9% of body weight over 68 weeks, roughly 37 lbs from a 250 lb starting weight.
What does the video say about surmount-1 trial (jastreboff et al., 2022, nejm): tirzepatide produced up?
SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM): tirzepatide produced up to 22.5% mean weight loss at the highest dose, significantly outperforming semaglutide in head-to-head comparisons.
What does the video say about step 4 trial (rubino et al., 2021, jama): stopping semaglutide?
STEP 4 trial (Rubino et al., 2021, JAMA): stopping semaglutide results in regain of approximately two-thirds of lost weight within one year, making the caption claim of losing 30 more lbs after stopping medication implausible for most people.
What does the video say about approximately 40% of weight lost on semaglutide in clinical trials?
Approximately 40% of weight lost on semaglutide in clinical trials is lean mass, which supports the creator's recommendation for resistance training as a preservation strategy.
What does the video say about the specific study citations in this video (a 1999 protein?
The specific study citations in this video (a 1999 protein study, a 2012 PCOS study) are presented without journal names or authors and cannot be independently verified as quoted.
What does the video say about 100 lbs of weight loss in 6 months falls well?
100 lbs of weight loss in 6 months falls well outside average clinical trial outcomes and represents an extreme outlier, not a reasonable expectation for most GLP-1 users.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dustin Holston the Biohacker, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.